StemSight secures new patents for scalable induced pluripotent stem cells-derived limbal stem cells, boosting STE-101’s path to off-the-shelf limbal stem cell deficiency therapy and upcoming Series A.

Patent milestones: granted in Singapore; notices of allowance in Canada and Japan; applications pending in Europe, the US, India, and South Korea. Technology: induced pluripotent stem cells-derived ...

Mark Barakat, MD, is a vitreoretinal surgeon and director of research at the Retina Macula Institute of Arizona, where he specializes in the surgical and medical management of complex retinal diseases ...

SOL-1 data show OTX-TKI extends rescue-free control in treatment-naive wet AMD, shaping AI-driven trial design and longer-interval care. Barakat opened by highlighting what makes CTS uniquely valuable ...

Learn how FDA’s interchangeable ranibizumab biosimilar may streamline injections, cut costs, and guide safe switching for retina patients. Following the FDA approval of ranibizumab-hkdz (Ranluspec; ...

A retrospective study identifies thin choroid as the key factor behind ungradable ultrawidefield green-light fundus autofluorescence images in geographic atrophy. This retrospective, cross-sectional ...

Alkeus Pharmaceuticals has dosed the first participant in the phase 3 NORTHSTAR trial of oral gildeuretinol for Stargardt disease, a condition with no approved treatments. Alkeus Pharmaceuticals in a ...

The US Food and Drug Administration (FDA) issued draft guidance to help developers bring promising gene therapies to patients more efficiently by making greater use of existing scientific and ...

The FDA has approved ranibizumab-hkdz (Ranluspec; Lupin Limited) as an interchangeable biosimilar for wet AMD, DME, DR, RVO, and mCNV.

In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Eichenbaum about the cell and gene therapy pipeline ahead, what sustains a career in ...

Meeting founder and co-chair Arshad M. Khanani, MD, MA, FASRS, shares what attendees can expect during this year's program, opening the evening of June 12 and running through June 13 in Las Vegas, ...

The FDA has approved ranibizumab-hkdz (Ranluspec; Lupin Limited) as an interchangeable biosimilar for wet AMD, DME, DR, RVO, and mCNV. The FDA has approved ranibizumab-hkdz (Ranluspec; Lupin Limited), ...